Axcella Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Out of Business

  • Employees
  • 11

Employees

  • Latest Deal Type
  • Liquidation

Axcella General Information

Description

Operator of a clinical-stage biotechnology company designed to help identify protein nutrients within the human diet that have potent pharmacological effects. The company focuses on treating complex diseases and improving health using endogenous metabolic modulators, or EMM, compositions.

Contact Information

Formerly Known As
Essentient, Pronutria
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 840 Memorial Drive
  • Entrance on Blackstone Street, Third Floor
  • Cambridge, MA 02139
  • United States
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Corporate Office
  • 840 Memorial Drive
  • Entrance on Blackstone Street, Third Floor
  • Cambridge, MA 02139
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Axcella Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Bankruptcy: Liquidation 28-Dec-2023 Completed Bankruptcy: Liquidation
10. 2PO 16-Mar-2022 Completed Generating Revenue
9. 2PO 14-May-2020 Completed Generating Revenue
8. IPO 09-May-2019 Completed Generating Revenue
7. Later Stage VC (Series E) 30-Nov-2018 Completed Generating Revenue
6. Debt Refinancing 09-Jan-2018 Completed Generating Revenue
5. Later Stage VC (Series D) 24-Feb-2016 Completed Clinical Trials - General
4. Later Stage VC (Series C) 17-Feb-2015 Completed Clinical Trials - General
3. Debt - General 30-Jun-2014 $7M $30M Completed Clinical Trials - General
2. Early Stage VC (Series B) 13-Feb-2014 $12.2M $23M Completed Clinical Trials - General
To view Axcella’s complete valuation and funding history, request access »

Axcella Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series E
Series D
Series C
Series B1
Series B 4,737,041 $0.001000 $0.21 $2.59 $2.59 1x $2.59 10.18%
Series A 5,874,334 $0.001000 $0.16 $1.95 $1.95 1x $1.95 12.62%
To view Axcella’s complete cap table history, request access »

Axcella Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a clinical-stage biotechnology company designed to help identify protein nutrients within the human diet tha
Biotechnology
Cambridge, MA
11 As of 2022

Vancouver, Canada
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Axcella Competitors (101)

One of Axcella’s 101 competitors is Genevant, a Corporate Backed or Acquired company based in Vancouver, Canada.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Genevant Corporate Backed or Acquired Vancouver, Canada
Vedanta Biosciences Venture Capital-Backed Cambridge, MA
Cellaion Formerly VC-backed Mont-Saint-Guibert, Belgium
Enterome Venture Capital-Backed Paris, France
4D pharma Corporation Leeds, United Kingdom
You’re viewing 5 of 101 competitors. Get the full list »

Axcella Patents

Axcella Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024030909-A1 Biomarkers of amino acid composition treatment response in long covid Inactive 01-Aug-2022
WO-2024026307-A1 Biomarker for long covid and fatigue Inactive 25-Jul-2022
WO-2023009444-A1 Amino acid compositions and methods for use in the treatment of post-acute sequelae of covid-19 Inactive 26-Jul-2021
WO-2022266480-A1 Methods of predicting liver fat content and uses thereof Inactive 17-Jun-2021
US-20230089723-A1 Amino acid compositions and methods for muscle and myotube modulation Inactive 06-Mar-2020 A61P21/00
To view Axcella’s complete patent history, request access »

Axcella Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Axcella ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Axcella’s complete esg history, request access »

Axcella FAQs

  • When was Axcella founded?

    Axcella was founded in 2008.

  • Where is Axcella headquartered?

    Axcella is headquartered in Cambridge, MA.

  • What is the size of Axcella?

    Axcella has 11 total employees.

  • What industry is Axcella in?

    Axcella’s primary industry is Biotechnology.

  • Is Axcella a private or public company?

    Axcella is a Private company.

  • What is Axcella’s current revenue?

    The current revenue for Axcella is .

  • How much funding has Axcella raised over time?

    Axcella has raised $325M.

  • Who are Axcella’s competitors?

    Genevant, Vedanta Biosciences, Cellaion, Enterome, and 4D pharma are some of the 101 competitors of Axcella.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process